08:36 AM EDT, 06/23/2025 (MT Newswires) -- Emergent BioSolutions ( EBS ) said Monday it received a $62.4 million contract modification from the Administration for Strategic Preparedness and Response, a division of the US Department of Health and Human Services, for the continued supply of its BAT botulism antitoxin.

The biopharmaceutical company said the modification amends an existing 10-year contract and supports the stockpiling of the treatment, which is used for confirmed or suspected exposure to botulinum neurotoxin serotypes A through G in both adults and children.

Share of the company were up 3.1% in recent premarket activity.